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Background-—Cardiac biomarkers are independent risk markers in atrial ﬁbrillation, and the novel biomarker–based ABC stroke
score (age, biomarkers, and clinical history of prior stroke) was recently shown to improve the prediction of stroke risk in patients
with atrial ﬁbrillation. Our aim was to investigate the short-term variability of the cardiac biomarkers and evaluate whether the ABC
stroke risk score provides a stable short-term risk estimate.
Methods and Results-—According to the study protocol, samples were obtained at entry and also at 2 months in 4796 patients
with atrial ﬁbrillation followed for a median of 1.8 years in the ARISTOTLE (Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation) trial. Cardiac troponin I, cardiac troponin T, and N-terminal pro-B-type natriuretic
peptide were measured with high-sensitivity immunoassays. Associations with outcomes were evaluated by Cox regression.
C indices and calibration plots were used to evaluate the ABC stroke score at 2 months. The average changes in biomarker levels
during 2 months were small (median change cardiac troponin T +2.8%, troponin I +2.0%, and N-terminal pro-B-type natriuretic
peptide +13.5%) and within-subject correlation was high (all ≥0.82). Repeated measurement of cardiac biomarkers provided some
incremental prognostic value for mortality but not for stroke when combined with clinical risk factors and baseline levels of the
biomarkers. Based on 8702 person-years of follow-up and 96 stroke/systemic embolic events, the ABC stroke score at 2 months
achieved a similar C index of 0.70 (95% CI, 0.65–0.76) as compared with 0.70 (95% CI, 0.65–0.75) at baseline. The ABC stroke
score remained well calibrated using predeﬁned risk classes.
Conclusions-—In patients with stable atrial ﬁbrillation, the variability of the cardiac biomarkers and the biomarker-based ABC
stroke score during 2 months are small. The prognostic information by the ABC stroke score remains consistent and well
calibrated with similar good predictive performance if patients are retested after 2 months.
Clinical Trial Registration -—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT00412984. ( J Am Heart Assoc. 2017;6:
e004851. DOI: 10.1161/JAHA.116.004851.)
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A trial ﬁbrillation (AF) is the most common sustainedarrhythmia and constitutes a major risk factor for stroke
and mortality.1,2 Cardiac biomarkers, troponin and natriuretic
peptides, have repeatedly been shown to provide independent
prognostic information for the risk of stroke, vascular events,
and mortality in patients with AF treated with
anticoagulation.3–6 Recently, a biomarker-based risk model
consisting of the 4 strongest predictors for stroke in patients
with AF was developed, the ABC stroke score (age, biomark-
ers [troponin and NT-proBNP (N-terminal pro-B-type natri-
uretic peptide)], and clinical history of prior stroke).7 The ABC
stroke score was derived in 14 701 patients, validated in 2
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external cohorts of 1400 and 8356 patients achieving C
indices between 0.65 and 0.68, and showed superiority over
contemporary risk scores.7,8 However, so far, there is no
information on the variability over time for these biomarkers
and the associations between changed levels and clinical
events in patients with stable AF. Therefore, the utility of
repeated measurements for reevaluation of the ABC stroke
score within different time frames needs to be evaluated
because changes of the biomarker levels and the ABC score
may be potentially useful for monitoring disease progress and
the effects of different treatments (eg, for hypertension, heart
failure, and rate control) both in clinical trials and in the
routine management of patients with AF.
In the present prespeciﬁed serial biomarkers substudy
within the ARISTOTLE (Apixaban for Reduction in Stroke and
Other Thromboembolic Events in Atrial Fibrillation) trial, we
investigated the changes in the concentrations of the cardiac
biomarkers, cardiac troponin (cTn) I (cTnI), cTn T (cTnT), and
NT-proBNP, at 2 months and whether the added information
improved the prognostication of outcomes in patients with AF
treated with anticoagulation. The availability of repeated
measurements also provided an opportunity to determine
whether the novel biomarker–based ABC stroke risk score
provided a stable estimate over a period of time.
Methods
The ARISTOTLE Trial
The details of the ARISTOTLE trial have been previously
published.9,10 Brieﬂy, ARISTOTLE was a double blind, double-
dummy, randomized clinical trial that enrolled 18 201
patients with AF and at least one CHADS2 risk factor
(congestive heart failure, hypertension, age ≥75 years, dia-
betes mellitus, prior stroke) for stroke or systemic embolism.
Patients were randomized to warfarin (n=9081) or apixaban
(n=9120). The primary end point was stroke or systemic
embolism. The median duration of follow-up was 1.8 years.
The biomarker serial substudy aimed to include 5000
patients to provide blood samples for later biomarker mea-
surements at randomization and at the preplanned outpatient
visit after 2 months. Details are provided in Figure 1.
Approval by the appropriate institutional review commit-
tees was obtained at all sites. All patients provided written
informed consent.
End Points
The end points in this substudy were new events after
2 months and included the primary efﬁcacy outcome in the
ARISTOTLE trial (stroke or systemic embolism) and the
secondary efﬁcacy outcomes (all-cause mortality and
cardiovascular death [excluding bleeding and other noncar-
diac causes]). A blinded clinical events committee using
prespeciﬁed criteria adjudicated all end points.10
Biochemical Methods
At randomization and at 2 months, blood samples were
collected in vacutainer tubes containing EDTA and were
centrifuged immediately. Plasma was frozen in aliquots and
stored at 70°C until analyzed centrally at the Uppsala
Clinical Research Center. The cTnI concentration was deter-
mined with high-sensitivity sandwich immunoassays on the
ARCHITECT i1000SR (Abbott Diagnostics). The dynamic range
is 0.7 to 50 000 ng/L, limit of detection in the Uppsala
Clinical Research Center laboratory 1.3 ng/L, and the 99th
percentile upper reference limit for healthy persons 23 ng/
L.11 The coefﬁcient of variation (CV) for this cTnI assay is 10%
at 3.3 with a local CV of 7% at 21 ng/L. The cTnT
concentration was determined with high-sensitivity sandwich
immunoassays on the Cobas Analytics e601 Immunoanalyz-
ers (Roche Diagnostics). The measuring range is 3 to
10 000 ng/L, limit of detection 5 ng/L, and the 99th
percentile upper reference limit for healthy persons 14 ng/
L.12 The CV is 10% at 13 ng/L with a local CV of 3% at 27 ng/
L. NT-proBNP concentration was determined on the Cobas
Analytics e601 Immunoanalyzers (Roche Diagnostics). The
limit of detection is 5 ng/L. The analytical range is 20 to
Total number of events in each biomarker group
cTnI
•Stroke/SE (n=94)
•All-cause mortality (n=265)
•Cardiovascular
mortality (n=125)
cTnT
•Stroke/SE (n=96)
•All-cause mortality (n=271)
•Cardiovascular
mortality (n=128)
NT-proBNP
•Stroke/SE (n=87)
•All-cause mortality (n=237)
•Cardiovascular
mortality (n=114)
Number of participants in is each biomarker group
cTnI (n=4648) cTnT (n=4790) NT-proBNP (n=4168)
Patients with cardiac biomarker samples at 2 months
(n=4868)
Serial biomarker substudy
(n=7203)
Biomarkers at randomization
(n=14,897 )
Participants in the ARISTOTLE trial
(n=18,201)
Figure 1. CONSORT ﬂow diagram of the number of participants
included in the serial biomarker substudy and total number of
patients with events after 2 months stratiﬁed for each biomarker.
ARISTOTLE indicates Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation; cTnI, cardiac tro-
ponin I; cTnT, cardiac troponin T; NT-proBNP, N-terminal pro-B-
type natriuretic peptide; SE, systemic embolism.
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35 000 ng/L. The upper reference limit is 269 in men and
391 ng/L in women.13 The CV is <10% at 30 ng/L with a
local CV of 3% at 27 ng/L.14
Statistical Analyses
The analyses included randomized patients with biomarkers
available at randomization and at 2 months follow-up. The
biomarkers were natural log transformed before analysis.
Associations between baseline characteristics and cTn or
NT-proBNP at 2 months were examined in linear regression
models where the biomarker at 2 months was a response
Table 1. Demographics and Clinical Characteristics at
Baseline
No. N=4796
Age, median (Q1–Q3), y 70.0 (63.0–76.0)
Male sex 3156 (65.8%)
Region, No. (%)
Asia/Pacific 684 (14.3)
Europe 2353 (49.1)
Latin America 419 (8.7)
North America 1340 (27.9)
Weight, median (Q1–Q3), kg 83.5 (71.3–96.6)
Renal function, median (Q1–Q3), mL/min
(n=4779)
75.5 (58.5–96.7)
Systolic blood pressure, median (Q1–Q3)
(n=4788)
130.0 (120–140)
Baseline heart rate, median (Q1–Q3), beats per
min (n=4785)
75.0 (65–85)
Smoker, No. (%) 424 (8.8)
Myocardial infarction, No. (%) 650 (13.6)
Prior stroke or TIA, No. (%) 853 (17.8)
Heart failure, No. (%) 1721 (35.9)
Diabetes mellitus, No. (%) 1194 (24.9)
Hypertension, No. (%) 4187 (87.3)
Permanent/persistent atrial fibrillation, No. (%) 4022 (83.9)
Prior VKA status, naive, No. (%) 1802 (37.6)
ACEI or ARB, No. (%) 3397 (70.8)
Aspirin, No. (%) 1401 (29.2)
hs Troponin I, median (Q1–Q3), ng/L (n=4744) 5.1 (3–9)
hs Troponin T, median (Q1–Q3), ng/L (n=4791) 10.8 (8–16)
GDF-15, median (Q1–Q3), ng/L (n=4764) 1363.5 (978–2038)
NT-proBNP, median (Q1–Q3), ng/L (n=4791) 713.0 (366–1231)
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; GDF, growth differentiation factor; hs, high-sensitivity; NT-proBNP, N-terminal
pro-B-type natriuretic peptide; TIA, transient ischemic attack; VKA, vitamin K antagonist.
A
B
C
Figure 2. Bland-Altman plot of the ratio between the 2-month
level and the baseline level against the geometric mean of the 2
observations for cardiac troponin I (cTnI) (A), cardiac troponin T
(cTnT) (B), and N-terminal pro-B-type natriuretic peptide
(NT-proBNP) (C). The dotted lines represent mean and 95% CI.
A, Association between continuous cTnI levels at baseline
(x axis) and cardiovascular mortality by group according to
changes of cTnI at 2 months (lines). B, Association between
continuous cTnT levels at baseline (x axis) and cardiovascular
mortality by group according to changes of cTnT at 2 months
(lines). C, Association between continuous NT-proBNP levels at
baseline (x axis) and cardiovascular mortality by group according
to changes of NT-proBNP at 2 months (lines).
DOI: 10.1161/JAHA.116.004851 Journal of the American Heart Association 3
Cardiac Biomarkers and ABC Stroke Score Over Time Hijazi et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on July 25, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
variable and the baseline characteristic, randomized treat-
ment, and biomarker at baseline were explanatory variables.
Geometric means, calculated by antilogarithms of the model-
adjusted means, were compared. Correlations between
biomarker changes were evaluated using the Spearman rank
correlation coefﬁcient. The intraindividual CV was estimated
by pooling individual CVs.
Analysis of clinical outcomes included all events from the
month 2 measurement until the efﬁcacy cutoff date. For
patients with events between randomization and month 2, the
ﬁrst event occurring after month 2 was counted as the ﬁrst
event.
The associations between cTn or NT-proBNP and events
after 2 months were investigated using Cox proportional
hazards regression adjusted for study treatment and baseline
levels of the respective biomarker. A relative change value of
50% was used in order to capture clinically signiﬁcant
changes.15–17 The increased discriminative value of month 2
measurement of each biomarker was estimated by comparing
Harrell’s C index before and after adding the month 2 value to
a model with the baseline value (both in continuous form),
randomized treatment, other biomarkers (cystatin C and
either cTnI or NT-proBNP), and established risk factors (for
stroke or systemic embolism outcomes collected at baseline
(age, sex, hypertension, diabetes mellitus, heart failure,
previous stroke/systemic embolism/transient ischemic
attack, and history of vascular disease). For all-cause
mortality and cardiovascular death, systolic blood pressure
and smoking status were also included. Restricted cubic
splines were used to allow for nonlinearities in the association
between continuous variables and outcomes. Likelihood ratio
tests were performed to evaluate whether the global model ﬁt
improved after the addition of the month 2 measurements of
each biomarker.
Table 2. Baseline Characteristic With Signiﬁcant Associations With the Continuous cTnI (ng/L) at Month 2 Adjusted for Baseline
cTnI Level and Randomized Treatment
Variable
Variable Value
at Baseline No.
Geometric
Mean
Ratio of Geometric
Means (95% CI) P Value*
Diabetes mellitus No 3495 6.0 <0.0001
Yes 1153 6.3 1.06 (1.03–1.09)
Prior myocardial infarction No 4013 6.0 0.0010
Yes 635 6.4 1.06 (1.03–1.10)
Prior stroke or systemic embolism No 3784 6.0 0.0120
Yes 864 6.3 1.04 (1.01–1.08)
Prior warfarin No 1740 6.0 0.0325
Yes 2908 6.1 1.03 (1.00–1.06)
Vascular disease No 3454 6.0 0.0008
Yes 1194 6.30 1.05 (1.02–1.08)
Renal function
Cystatin C (quartiles), mg/L
≤0.82 1179 6.0 0.0106
0.83–0.99 1123 5.9 0.99 (0.95–1.04)
1.0–1.2 1180 6.1 1.02 (0.98–1.07)
>1.2 1160 6.3 1.05 (1.01–1.10)
NT-proBNP (quartiles), ng/L ≤363 1158 4.6 0.5973
364–713 1174 5.4 1.00 (0.96–1.04)
714–1250 1183 6.2 1.02 (0.97–1.06)
>1250 1128 8.9 1.02 (0.97–1.07)
Troponin T (quartiles), ng/L ≤7.5 1188 5.8 0.0007
7.6–11.0 1205 6.0 1.02 (0.98–1.06)
11.1–16.7 1180 6.2 1.06 (1.01–1.10)
>16.7 1072 6.4 1.09 (1.04–1.15)
cTnI indicates cardiac troponin I; NT-proBNP indicates N-terminal pro-B-type natriuretic peptide.
*P value from a linear regression model with the natural logarithm of the month 2 biomarker as the outcome variable and log baseline biomarker level and speciﬁc baseline characteristic
as the independent variables.
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The validation of the ABC stroke score at 2 months was
performed by applying the prediction model using the
measurements at 2 months. Discrimination was assessed
by Harrell’s C index18 and by comparing Kaplan–Meier curves
and hazard ratios between the predeﬁned risk categories.7,19
Clinical usefulness and net beneﬁt were estimated with
decision curve analysis.20 Calibration was assessed by
comparing observed 1-year event rates with predictions from
the ﬁnal model.
A P value <0.05 from 2-sided tests was considered
statistically signiﬁcant. Since the analyses were exploratory,
the P values were not adjusted for multiple comparisons. All
analyses were performed at Uppsala Clinical Research Center
using SAS version 9.4 for Windows (SAS Institute Inc) and R
version 3.3 (The R Foundation).
Results
Baseline Characteristics
Baseline characteristics, medications, and concentration of
the cardiac biomarkers for the serial biomarker cohort are
shown in Table 1. At consent, the median age of patients was
70 years (25th percentile–75th percentile, 63–76), 3156
(65.8%) were men, and 3693 (77%) were from Europe/North
America.
Table 3. Baseline Characteristic With Signiﬁcant Associations With the Continuous cTnT (ng/L) at Month 2 Adjusted for Baseline
cTnT Level and Randomized Treatment
Variable Variable Value at Baseline No. Geometric Mean Ratio of Geometric Means (95% CI) P Value*
Age category, y <65 1464 11.1 <0.0001
65–74 1892 11.7 1.05 (1.03–1.08)
≥75 1434 12.3 1.11 (1.08–1.13)
Atrial fibrillation Paroxysmal 773 11.4 0.0225
Persistent/permanent 4016 11.7 1.03 (1.00–1.05)
Current smoker No 4366 11.7 0.0397
Yes 423 11.4 0.97 (0.94–1.00)
Diabetes mellitus No 3598 11.5 <0.0001
Yes 1192 12.1 1.05 (1.03–1.07)
Prior warfarin use No 1796 11.4 <0.0001
Yes 2994 11.9 1.04 (1.02–1.06)
Sex Female 1638 11.4 0.0001
Male 3152 11.8 1.03 (1.02–1.05)
Vascular disease No 3565 11.6 0.0030
Yes 1225 11.9 1.03 (1.01–1.05)
Renal function
Cystatin C (quartiles), mg/L
≤0.82 1208 11.9 0.0274
0.83–0.99 1159 11.5 0.97 (0.94–0.99)
1.0–1.2 1224 11.6 0.98 (0.95–1.01)
>1.2 1196 11.8 0.99 (0.96–1.02)
NT-proBNP (quartiles), ng/L ≤363 1188 11.6 0.7181
364–713 1208 11.7 1.00 (0.98–1.03)
714–1250 1224 11.7 1.01 (0.98–1.04)
>1250 1168 11.8 1.01 (0.98–1.04)
Troponin I (quartiles), ng/L ≤3.3 1302 11.2 <0.0001
3.4–5.4 1222 11.6 1.03 (1.00–1.06)
5.5–10.1 1173 12.1 1.07 (1.04–1.10)
>10.1 1043 12.0 1.06 (1.03–1.10)
cTnT indicates cardiac troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
*P value from a linear regression model with the natural logarithm of the month 2 biomarker as outcome variable and log baseline biomarker level and the speciﬁc baseline characteristic
as independent variables.
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Changes of cTn and NT-proBNP Levels Over Time
in AF
The median cTnI level at entry was 5.1 ng/L (25th–75th
percentile, 3.2–9.1 ng/L). At 2 months’ follow-up, median
levels were slightly higher at 5.2 ng/L (3.4–8.9 ng/L),
geometric mean change was 1.02 (95% CI, 1.00–1.03),
CV was 7.6%, and within-subject correlation was 0.87. For
cTnT, the median level at entry was 10.8 ng/L (7.5–16.1
ng/L) and after 2 months was 11.1 ng/L (7.9–16.9 ng/
L), geometric mean change was 1.03 (95% CI, 1.02–1.04),
CV was 3.6%, and within-subject correlation was 0.88.
Median NT-proBNP level at entry was 702 ng/L (362–
1215 ng/L) and 797 ng/L (392–1327 ng/L) after
2 months, geometric mean change was 1.10 (95% CI,
1.08–1.12), CV was 14.4%, and within-subject correlation
was 0.82. The agreements between the biomarker con-
centrations at baseline and after 2 months are shown in
Figure 2A through 2C.
There was a positive correlation between changes in cTnI
and cTnT concentrations, Spearman q=0.45. The correlation
between changes in NT-proBNP and changes in cTn was lower
(cTnI q=0.15 and cTnT q=0.17).
The randomized treatment group (apixaban or warfarin)
had no statistically signiﬁcant relationship with the change in
biomarker concentration at 2 months’ follow-up (all
P≥0.1272).
Determinants of Increased Levels of cTn and
NT-proBNP at Follow-Up
The effect of baseline characteristics on cTn and NT-proBNP
levels at 2 months’ follow-up was assessed with linear
regression adjusted for baseline levels of each respective
biomarker (Table 2–4). For both cTnI and cTnT, presence of
coronary artery disease and diabetes mellitus as well as
baseline troponin were associated with higher levels at
2 months’ follow-up. Furthermore, prior stroke and prior
myocardial infarction were associated with higher cTnI values
in particular at follow-up, while higher age, male sex, and
lower hematocrit level were associated with higher cTnT levels
at follow-up. Higher NT-proBNP levels at 2 months were
Table 4. Baseline Characteristic With Signiﬁcant Associations With the Continuous NT-proBNP (ng/L) at Month 2 Adjusted for
Baseline NT-proBNP Level and Randomized Treatment
Variable
Variable Value
at Baseline No.
Geometric
Mean
Ratio of Geometric
Means (95% CI) P Value*
Age category, y <65 1277 619.9 <0.0001
65–74 1635 667.9 1.08 (1.02–1.13)
≥75 1256 747.8 1.21 (1.14–1.27)
Atrial fibrillation Paroxysmal 700 545.3 <0.0001
Persistent/permanent 3467 705.3 1.29 (1.22–1.37)
Heart failure No 2891 667.9 0.0778
Yes 1277 692.7 1.04 (1.00–1.08)
Sex Female 1460 696.8 0.0150
Male 2708 664.2 0.95 (0.92–0.99)
Renal function Cystatin C
(quartiles), mg/L
≤0.82 1081 713.3 <0.0001
0.83–0.99 1007 643.7 0.90 (0.85–0.96)
1.0–1.2 1057 635.2 0.89 (0.84–0.95)
>1.2 1022 712.6 1.00 (0.93–1.07)
Troponin I (quartiles), ng/L ≤3.3 1131 618.5 <0.0001
3.4–5.4 1060 676.7 1.09 (1.03–1.16)
5.5–10.1 1034 701.5 1.13 (1.06–1.21)
>10.1 907 717.0 1.16 (1.08–1.24)
Troponin T (quartiles), ng/L ≤7.5 1078 629.5 <0.0001
>7.5–11.0 1088 657.4 1.04 (0.98–1.11)
>11.0–16.7 1041 687.6 1.09 (1.02–1.16)
>16.7 959 738.1 1.17 (1.10–1.25)
NT-proBNP indicates N-terminal pro-B-type natriuretic peptide.
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mainly affected by age, type of AF (persistent or permanent),
and baseline cTn levels.
Changes of Cardiac Biomarker Levels Over Time
and Association With Cardiovascular Risk
In Cox regression analyses adjusted for baseline concentra-
tions of NT-proBNP and randomized treatment, there was a
positive association between risk of stroke or systemic
embolism and NT-proBNP at month 2 (hazard ratio per 50%
increase 1.24; 95% CI, 1.05–1.45 [P=0.0093]). For cTnI and
cTnT, the association was attenuated (hazard ratio, 1.12 [95%
CI, 0.98–1.29] and hazard ratio, 1.21 [95% CI, 0.98–1.49]),
respectively. However, the association was more pronounced
for cardiovascular mortality for NT-proBNP as well as the cTn
biomarkers (Table 5). The association between cardiovascular
mortality and changes of cTn and NT-proBNP levels at
2 months according to continuous level of the biomarker at
baseline is illustrated in Figure 3A through 3C.
Prognostic Discrimination Using Repeated
Measurement of Cardiac Biomarkers
According to C indices, all 3 biomarkers showed similar
discriminatory properties at baseline and after 2 months for
the risks of stroke and cardiovascular mortality during
follow-up after the 2-month visit. Addition of information
from the repeated cTn or NT-proBNP measurement to
baseline level on top of established risk factors and other
baseline biomarkers (NT-proBNP and cystatin C for cTn; cTnI
and cystatin C for the NT-proBNP-15 analyses) did not
improve the prognostication sufﬁciently for stroke or
systemic embolism (no improvement in C index and/or
P≥0.1031). For cardiovascular death, repeated measurement
of the cardiac biomarkers at 2 months improved the C index
slightly (cTnI 0.78 to 0.80 and cTnT 0.77 to 0.78; NT-proBNP
0.78 to 0.79 with statistically signiﬁcant model improvement
[P≤0.0006 for all]).
Discrimination and Calibration of the ABC Stroke
Score at 2-Month Follow-Up
The newly developed biomarker-based stroke risk model, the
ABC stroke score, was assessed in this cohort with a total of
8702 person-years of follow-up and a total of 96 adjudicated
stroke or systemic embolic events after the blood sampling
at 2 months. Using information from the cardiac biomarker
levels at 2 months yielded a C index for the ABC stroke
score of 0.72 (95% CI, 0.66–0.77) including cTnI and 0.70
(95% CI, 0.65–0.76) including cTnT. The C index for the ABC
stroke score using data at baseline was almost identical,
with cTnI 0.71 (95% CI, 0.66–0.76) and cTnT 0.70 (95% CI,
0.65–0.75). The similarity between the predicted risks of
ABC stroke score at baseline and after 2 months is
illustrated in Figure 4. Most predictions, 94.7%, differed less
than a factor of 1.5 between the 2 measurement periods
(Figure 4). The ABC stroke score at 2 months showed good
calibration according to predeﬁned risk classes (Figure 5).
Similarly, decision curve analysis showed consistent net
beneﬁt for clinical usefulness when reassessing the ABC
stroke score at 2 months compared with the ABC stroke
score at baseline (Figure 6).
Table 5. Relation to Cardiovascular Outcomes Per 50% Increase in cTnT and NT-proBNP Month 2 Levels
Biomarker/Outcome No. Events (%/y) HR (95% CI) P Value
NT-proBNP
Stroke or systemic embolism 4168 87 (1.15) 1.24 (1.06–1.45) 0.0076
Death 4168 237 (3.09) 1.30 (1.18–1.43) <0.0001
Cardiovascular death 4168 114 (1.49) 1.36 (1.18–1.57) <0.0001
cTnI
Stroke or systemic embolism 4648 94 (1.11) 1.12 (0.98–1.29) 0.1079
Death 4648 265 (3.10) 1.18 (1.10–1.28) <0.0001
Cardiovascular death 4648 125 (1.46) 1.24 (1.13–1.37) <0.0001
cTnT
Stroke or systemic embolism 4790 96 (1.11) 1.21 (0.98–1.49) 0.0745
Death 4790 271 (3.08) 1.40 (1.26–1.56) <0.0001
Cardiovascular death 4790 128 (1.46) 1.50 (1.30–1.74) <0.0001
Hazard ratios (HRs) per 50% increase in biomarker level at month 2 with 95% CIs and P values from Cox proportional hazards model adjusted for randomized treatment and baseline
biomarker (continuous, log-transformed). cTnI indicates cardiac troponin I; cTnT, cardiac troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
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Discussion
The main ﬁndings in this study were that the changes of
cardiac biomarker levels in patients with stable AF during
2 months were small and that there was low intraindividual
variability. Increasing cTn levels were associated with higher
baseline cTn levels, renal dysfunction, and cardiovascular
comorbidities. Increasing levels of NT-proBNP were mainly
associated with higher baseline cTn levels, older age, and
persistent or permanent AF. In patients with AF in stable
condition, repeated measurement of the cardiac biomarkers
cTn and NT-proBNP provided some incremental prognostic
value for mortality but not for stroke when combined with
other prognostic biomarkers and established clinical risk
factors. The biomarker-based ABC stroke risk score showed a
reliable and stable predictive performance and remained well
calibrated when reevaluated after 2 months.
Repeated Measurements of cTn and
Cardiovascular Risk
It has been demonstrated in patients with AF that cTn
measured with high-sensitivity assays is independently asso-
ciated with the risk of stroke, mortality, and major bleeding
events.4,5 We recently reported that a detectable level of cTnI
during follow-up as measured with a conventional assay
(AccuTnI assay, Beckman Coulter) was associated with an
increased risk of stroke and cardiovascular events.21 By using
high-sensitivity cTn assays in the present study, in which more
than 93% have detectable levels,4,5 a more detailed analysis
was possible concerning changes of troponin during a short
period in a clinical setting. In both the RE-LY (Randomized
A
B
C
Figure 3. Association between continuous biomarker levels at
baseline (x-axis) and cardiovascular mortality by group according
to increase of each biomarker at 2 months (red lines) for (A) cTnI,
(B) cTnT, and (C) NT-proBNP. NT-proBNP indicates N-terminal
pro-B-type natriuretic peptide.
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Figure 4. Bland-Altman plot of the log ratio (difference in log-
predicted ABC [age, biomarkers, and clinical history of prior
stroke] risk) between the 2-month and baseline estimates of the
1-year risk of stroke or systemic embolism against the geometric
mean of the 2 estimates. The dashed lines indicate the mean and
the 2-SDs distance from the mean. The red line indicates locally
weighted scatterplot smoothing. Cardiac troponin T was used in
the ABC stroke score.
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Evaluation of Long-Term Anticoagulation Therapy) and the
present study, repeated measurement of cTnI improved risk
stratiﬁcation in patients with AF for cardiovascular mortality.
However, there was seemingly a discrepancy between these
studies concerning the ﬁndings for stroke or systemic
embolism. In the RE-LY study, but not in the present serial
markers substudy, a signiﬁcant association between cTn and
stroke or systemic embolism was seen. The differences are
reasonably attributable to the vastly improved risk prediction
gained by the initial cTnI measurement at baseline by using
high-sensitivity assays compared with the conventional
troponin assays. This was apparent as the C index for stroke
or systemic embolism improved from 0.59 to 0.63 in the
RE-LY study using the conventional cTnI assay, compared with
a C index from 0.69 to 0.70 using high-sensitivity assays in
the present study.
The present ﬁndings demonstrating additive prognostic
information of repeat measurement for the risk of cardiovas-
cular mortality in patients with AF are in accordance with
ﬁndings in previous studies with other patient populations, eg,
those with coronary artery disease and heart failure and in
apparently healthy adults, in which serial measurements of
cTn have been shown to be powerful markers of mortality and
morbidity.15,22–24 Our ﬁndings in the present study therefore
extend these observations to a novel population and validate
previous results by displaying the prognostic importance of a
repeated measurement of cTn in patients with AF related to
mortality risk.
Figure 5. Cumulative event rate of stroke or systemic embolism by predicted 1-year ABC (age,
biomarkers, and clinical history of prior stroke) risk (cardiac troponin T) group (green=0–1%, blue=1–2%,
and red >2%) for the baseline (dashed lines) and temporal validation (solid lines) data. The ﬁgure shows the
cumulative event rate within risk classes for the ABC stroke model evaluated independently at the 2 time
points. It illustrates that the model performs equally well when it is applied using biomarker values at
baseline as when it is applied using biomarker values at 2 months. SE indicates systemic embolism.
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The additive value of repeated measurement was overall
similar for cTnI and cTnT, with some potential differences of
risks at different concentrations. There are some structural
differences between cTnI and cTnT as well as differences in
the assay properties that may contribute to these dissim-
ilarities and provide insights into the moderate correlation
between the 2 cTn subtypes.25 The speciﬁc mechanism of
elevated cTn in patients with AF is not known. It has been
hypothesized that it might be related to changes in
microvascular blood ﬂow and myocyte ischemia and dys-
function, and possibly linked to underlying processes of
atrial inﬂammation and ﬁbrosis in AF.26,27 Even though the
average change during 2 months for cTn was small, there
were some differences between the determinants for
increasing levels of cTnI and cTnT. Recently, similar patterns
between cTnI and cTnT have also been described in AF,
although these ﬁndings are restricted by analyses based on
single measurements.28
Repeated Measurement of NT-proBNP and
Cardiovascular Risk
NT-proBNP has demonstrated a strong independent associ-
ation with risk of stroke and mortality in patients with AF.3,6
Recently, we also reported that an elevated level during
follow-up was associated with an increased risk of stroke
and cardiovascular events.21 In the present study, using
repeated measurement, we demonstrated that the variability
of NT-proBNP over time is low, and that risk stratiﬁcation
improves for stroke and mortality in patients with AF during
treatment with anticoagulation. In this study, as compared
with the RE-LY biomarker substudy, we assessed the actual
change in NT-proBNP levels, accounting for analytical
imprecision and, importantly, also adjusting the analysis
for the levels of NT-proBNP at baseline. The differences in
the predictive importance most likely depends on the use of
a larger number of clinical risk indicators (demographic
variables and comorbidities) as well as the inclusion of
biomarkers with high-sensitivity assays in the baseline model
before assessing the added value of repeated NT-proBNP
measurements.
The ABC Stroke Score Over Time
This study presents the ﬁrst temporal validation of the novel
biomarker–based ABC stroke score for estimating the risk of
stroke in patients with AF. Although cardiac biomarkers are
powerful predictors of risk of stroke in patients with AF,
analytical and temporal variation might inﬂuence the clinical
usefulness of a score composed of biomarkers. However, there
is an abundance of data demonstrating the stability of these
analytes and the high precision in the used assays.25,28–30 We
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Figure 6. Decision curve analysis for the ABC stroke score (age, biomarkers, and clinical history of prior
stroke) (cardiac troponin T) applied at baseline (red) and at 2 months (blue).
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showed that the levels of cardiac biomarkers overall remain
stable with a relatively low CV and a high within-subject
correlation in patients with stable AF during 2 months of
follow-up. The biomarker-based ABC stroke score remained
well calibrated over time and provided similar clinical
usefulness. The majority of patients had similar predicted
risk of stroke using the ABC stroke score at baseline and at
2 months. Therefore, from a clinical perspective, short-term
routine reassessment does not seem necessary in patients
with stable AF. The results also support that reliable and
similar prognostic information is obtained by biomarker
determinations at different time points during the course of
the disease.
Limitations
Our results were derived from a clinical trial population of
consenting patients with AF and at least 1 risk factor for
stroke and therefore may not apply to a general unselected
population. The change of the biomarker concentrations
over time may be inﬂuenced by the analytical imprecision.
Similarly, parts of the observed differences between cTnI
and cTnT may be attributable to analytical differences
between the assays rather than biological differences.
However, both troponins were analyzed using high-sensitiv-
ity assays with high precision in the same plasma samples.
Within the ARISTOTLE trial, repeated sampling of biomark-
ers was prespeciﬁed at 2 months; therefore, the impor-
tance of long-term (12 months or longer) changes of
cardiac biomarkers in patients with AF may thus differ
and requires further investigation. Nonetheless, the present
results provide valuable information from a clinical per-
spective on the short-term stability of these biomarkers in
patients with AF and on the consistent risk prediction with
the ABC stroke score.
Conclusions
In patients with stable AF, the variability of the levels of the
cardiac biomarkers cTn and NT-proBNP levels during
2 months is small. Repeated measurements of these cardiac
biomarkers do not seem useful for monitoring the risk of
stroke, although it might be useful for improved information
on the risk of cardiovascular mortality. The ABC stroke risk
score provides reliable and stable prognostic information at
different time points, and reassessment of stroke risk by
repeating the ABC stroke score is overall not routinely
required in patients with stable AF within a short time
frame such as 2 months. Whether biomarker retesting at
a later time point or after a change in clinical status would
add additional prognostic information requires further
investigation.
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